| Project/Area Number |
15K11309
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Research Field |
Surgical dentistry
|
|---|
| Research Institution | Niigata University |
|---|
Principal Investigator |
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
芳澤 享子 松本歯科大学, 歯学部, 教授 (60303137)
中田 光 新潟大学, 医歯学総合病院, 教授 (80207802)
武井 延之 新潟大学, 脳研究所, 准教授 (70221372)
|
|---|
| Research Collaborator |
IZUMI Kenzi
ITO Yuko
YAMAMOTO Youka
OHHASHI Riuko
HUJIMOTO Yoko
WATANABE Mari
|
|---|
| Project Period (FY) |
2015-04-01 – 2019-03-31
|
| Project Status |
Completed (Fiscal Year 2018)
|
| Budget Amount *help |
¥4,810,000 (Direct Cost: ¥3,700,000、Indirect Cost: ¥1,110,000)
Fiscal Year 2017: ¥1,040,000 (Direct Cost: ¥800,000、Indirect Cost: ¥240,000)
Fiscal Year 2016: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000)
Fiscal Year 2015: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000)
|
|---|
| Keywords | mTOR阻害剤 / 口内炎 / 口腔粘膜細胞培養 / シロリムス / 有害事象 / 発症機序 / ヒト口腔粘膜上皮細胞培養 / リンパ脈管筋腫症 |
|---|
| Outline of Final Research Achievements |
As a basic experiment in vitro for sirolimus stomatitis, oral mucosal cells were cultured from 7 passages to 8 passages. Sirolimus was added onto the cultured cells, and the reaction of the cultured cells was observed. As a result, the doubling time of cell proliferation was prolonged by 5 times at 10 nM compared to 0 nM. The DNA synthesis ability decreased by about 20%. The morphology was spindle-shaped and many large cells at 0 nM, and small spherical cells increased at 1 nM or more. The area of the nuclei was significantly smaller at 10 nM compared to sirolimus 0 nM. The area of the cells was significantly smaller at 0.1 nM, 1 nM and 10 nM compared to sirolimus 0 nM. Furthermore, the expression of E-Cadherin was suppressed, and cell-cell adhesion was weakened.
|
| Academic Significance and Societal Importance of the Research Achievements |
申請者らは、リンパ脈管筋腫症に対するmTOR阻害剤の日米加共同MILES試験の日本側代表として試験の成功に貢献し、ついで安全性確立を目的とした医師主導治験を実施し、LAMに対する世界初の薬事承認に繋げた。その後、結節性硬化症の血管線維腫に対する外用が承認された。現在、難治性リンパ管疾患、限局性皮質異形成II型のてんかん発作、進行性骨化性線維異形成症に対する医師主導治験が進行中であり、益々適応拡大が予想される。mTOR阻害剤により高頻度に発症する有害事象の一つに口内炎があり、患者のQOLを著しく低下させている。mTOR阻害剤による口内炎の発症機序の解明と治療・予防法の確立は喫緊の課題である。
|
